The role of cell cycle regulatory proteins in the pathogenesis of melanoma

被引:98
作者
Li, Wei
Sanki, Amira
Karim, Rooshdiya Z.
Thompson, John F.
Lee, C. Soon
Zhuang, Liqing
McCarthy, Stanley W.
Scolyer, Richard A.
机构
[1] Royal Prince Alfred Hosp, Dept Anat Pathol, Camperdown, NSW 2050, Australia
[2] Royal Prince Alfred Hosp, Sydney Melanoma Unit, Camperdown, NSW 2050, Australia
[3] Royal Prince Alfred Hosp, Melanoma & Skin Canc Res Inst, Camperdown, NSW 2050, Australia
[4] Univ Sydney, Discipline Surg, Sydney, NSW 2006, Australia
[5] Univ Sydney, Discipline Pathol, Sydney, NSW 2006, Australia
基金
英国医学研究理事会;
关键词
pRb; p16; cyclin D1; p27; p53; p21; melanoma; pathogenesis; prognosis; immunohistochemistry;
D O I
10.1080/00313020600817951
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The transformation of melanocytes to melanoma cells is characterised by abnormal proliferation resulting from alterations in cell cycle regulatory mechanisms. This occurs through alterations in the two major cell cycle regulatory pathways, the retinoblastoma ( Rb) and p53 tumour suppressor pathways. This review summarises the current knowledge of alterations in these two pathways at G1/S transition and specifically the role of the key cell cycle regulatory proteins pRb, p16(INK4a) ( p16), cyclin D1, p27(Kip1) ( p27), p53 and p21(Waf1/Cip1) (p21) in the pathogenesis of melanoma. It also considers their prognostic significance. Current data indicate that alterations of cyclin kinase inhibitor (cdki) levels are implicated in the pathogenesis of melanoma and may be useful prognostic markers. However, large validation studies linked to comprehensive clinical follow up data are necessary to clarify the prognostic significance of cell cycle regulatory proteins in individual patients.
引用
收藏
页码:287 / 301
页数:15
相关论文
共 221 条
[1]   CDKN2A variants in a population-based sample of queensland families with melanoma [J].
Aitken, J ;
Welch, J ;
Duffy, D ;
Milligan, A ;
Green, A ;
Martin, N ;
Hayward, N .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (05) :446-452
[2]  
Akslen LA, 1998, INT J CANCER, V79, P91
[3]   P53 IMMUNOSTAINING IN MELANOCYTIC LESIONS [J].
AKSLEN, LA .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (04) :652-653
[4]   MUTATION AND EXPRESSION OF THE P53 GENE IN HUMAN-MALIGNANT MELANOMA [J].
ALBINO, AP ;
VIDAL, MJ ;
MCNUTT, NS ;
SHEA, CR ;
PRIETO, VG ;
NANUS, DM ;
PALMER, JM ;
HAYWARD, NK .
MELANOMA RESEARCH, 1994, 4 (01) :35-45
[5]   Progression in cutaneous malignant melanoma is associated with distinct expression profiles -: A tissue microarray-based study [J].
Alonso, SR ;
Ortiz, P ;
Pollán, M ;
Pérez-Gómez, B ;
Sánchez, L ;
Acuña, MJ ;
Pajares, R ;
Martínez-Tello, FJ ;
Hortelano, CM ;
Piris, MA ;
Rodríguez-Peralto, JL .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (01) :193-203
[6]  
Bachmann IM, 2004, INT J ONCOL, V25, P1559
[7]   Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma [J].
Baldi, A ;
Santini, D ;
Battista, T ;
Dragonetti, E ;
Ferranti, G ;
Petitti, T ;
Groeger, AM ;
Angelini, A ;
Rossiello, R ;
Baldi, F ;
Natali, PG ;
Paggi, MG .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2001, 83 (03) :364-372
[8]   High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas [J].
Bales, ES ;
Dietrich, C ;
Bandyopadhyay, D ;
Schwahn, DJ ;
Xu, WD ;
Didenko, V ;
Leiss, P ;
Conrad, N ;
Pereira-Smith, O ;
Orengo, I ;
Medrano, EE .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (06) :1039-1046
[9]  
Bartek J, 1999, J PATHOL, V187, P95, DOI 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO
[10]  
2-#